Clopidogrel (Plavix)

Jules Comin; D. Kallmes

doi:10.3174/ajnr.A2913

Clopidogrel (Plavix)

Jules Comin, D. Kallmes

Radiology

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.

Original language	English (US)
Pages (from-to)	2002-2004
Number of pages	3
Journal	American Journal of Neuroradiology
Volume	32
Issue number	11
DOIs	https://doi.org/10.3174/ajnr.A2913
State	Published - Dec 2011

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Clinical Neurology

Access to Document

10.3174/ajnr.A2913

Cite this

@article{3edaac8c994e44889f682280a44823b5,

title = "Clopidogrel (Plavix)",

abstract = "Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.",

author = "Jules Comin and D. Kallmes",

year = "2011",

month = dec,

doi = "10.3174/ajnr.A2913",

language = "English (US)",

volume = "32",

pages = "2002--2004",

journal = "American Journal of Neuroradiology",

issn = "0195-6108",

publisher = "American Society of Neuroradiology",

number = "11",

}

TY - JOUR

T1 - Clopidogrel (Plavix)

AU - Comin, Jules

AU - Kallmes, D.

PY - 2011/12

Y1 - 2011/12

N2 - Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.

AB - Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.

UR - http://www.scopus.com/inward/record.url?scp=84455188656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84455188656&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A2913

DO - 10.3174/ajnr.A2913

M3 - Review article

C2 - 22135129

AN - SCOPUS:84455188656

SN - 0195-6108

VL - 32

SP - 2002

EP - 2004

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

IS - 11

ER -

Clopidogrel (Plavix)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this